Methodological Issues and Controversies in Clinical Trials with Child and Adolescent Patients with Bipolar Disorder: Report of a Consensus Conference
Authors:
- Gabrielle A. CarlsonGCGabrielle A. Carlson
- Peter S. JensenPJPeter S. Jensen
- Robert L. FindlingRFRobert L. Findling
- Roger E. MeyerRMRoger E. Meyer
- Joseph CalabreseJCJoseph Calabrese
- Melissa P. DelBelloMDMelissa P. DelBello
- Graham EmslieGEGraham Emslie
- Laurie FlynnLFLaurie Flynn
- Frederick GoodwinFGFrederick Goodwin
- Martha HellanderMHMartha Hellander
- Robert KowatchRKRobert Kowatch
- Vivek KusumakarVKVivek Kusumakar
- 1 March 2003
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 13 (1) , 13-27
Abstract
Objective: To achieve consensus among researchers, pharmaceutical industry representatives, federal regulatory agency staff, and family advocates on a template for clinical trials of acute mania/bipolar disorder in children and adolescents. Method: The American Academy of Child and Adolescent Psychiatry, in collaboration with Best Practice, convened a group of experts from the key stakeholder communities (including adult psychiatrists with expertise in bipolar disorder) and assigned them to workgroups to examine core methodological issues surrounding the design of clinical trials and, ultimately, to generate a consensus statement encompassing: (1) inclusion/exclusion criteria, (2) investigator training needs and site selection, (3) assessment and outcome measures, (4) protocol design and ethical issues unique to trials involving children/adolescents, and (5) regulatory agency perspectives on these deliberations. Results: Conference participants reached agreement on 18 broad methodological questions. Key points of consensus were to assign priority to placebo-controlled studies of acute manic episodes in children and adolescents aged 10-17 years, who may or may not be hospitalized, and who may or may not suffer from common comorbid psychiatric disorders; to require that specialist diagnostic "gatekeepers" screen youths' eligibility to participate in trials; to monitor interviewer and rater competency over the course of the trial using agreed upon standards; and to develop new tools for assessment, including scales to measure aggression/rage and cognitive function, while using the best available instruments (e.g., Young Mania Rating Scale) in the interim. Conclusions: Methodologically rigorous, large-scale clinical trials of treatment of acute mania are urgently needed to provide information regarding the safety and efficacy, in youth, of diverse agents with potential mood-stabilizing properties.Keywords
This publication has 25 references indexed in Scilit:
- Mania and ADHD: comorbidity or confusionJournal of Affective Disorders, 1998
- Resolved: Mania Is Mistaken for ADHD in Prepubertal ChildrenJournal of the American Academy of Child & Adolescent Psychiatry, 1998
- The clinician-administered rating scale for mania (CARS-M): Development, reliability, and validityBiological Psychiatry, 1994
- Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group1994
- The Manchester nurse rating scales for the daily simultaneous assessment of depressive and manic ward behavioursJournal of Affective Disorders, 1988
- Behavioral Efficacy of Haloperidol and Lithium CarbonateArchives of General Psychiatry, 1984
- The Bech‐Rafaelsen Mania Scale and the Hamilton Depression ScaleActa Psychiatrica Scandinavica, 1979
- A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALEActa Psychiatrica Scandinavica, 1978
- A new scale for measuring maniaPsychological Medicine, 1977
- Assessing Clinical Characteristics of the Manic StateAmerican Journal of Psychiatry, 1971